Sun Pharma intimation of arrest of Independent Director Gautam Doshi
Sun Pharmaceutical Industries Ltd disclosed the arrest of Independent Director Gautam Doshi, stating the matter is unrelated to operations and will not impact the company or its Board processes. The intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with exchanges on June 14, 2026. The company will monitor the situation and take appropriate steps based on further developments.
*this image is generated using AI for illustrative purposes only.
Sun Pharmaceutical Industries Ltd disclosed the arrest of its Independent Director, Mr. Gautam Doshi. The company clarified that the matter is not connected with its operations and no impact is envisaged on the company or its Board processes. The information was submitted to the National Stock Exchange of India Limited and BSE Limited on June 14, 2026.
The intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sun Pharmaceutical Industries Limited stated that it will continue to monitor the situation. Appropriate steps will be taken by the company based on further developments regarding the arrest.
The filing was signed by Anoop Anjanikumar Deshpande, Company Secretary and Compliance Officer, on behalf of Sun Pharmaceutical Industries Limited.
Historical Stock Returns for Sun Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.29% | +0.67% | -4.13% | +0.20% | +6.85% | +167.48% |
What potential reputational risks could Sun Pharma face despite the company's assertion that operations are unaffected?
How might investors react to the arrest of an Independent Director in terms of stock volatility?
Could this event trigger increased scrutiny from regulatory bodies on Sun Pharma's governance practices?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
